Paola Queirolo

Paola Queirolo

European Institute of Oncology Milan - Milan / Italy
Others
AD Scientific Index ID: 4686757
person_outline Paola Queirolo's MOST POPULAR ARTICLES
1-) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaJ Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...New England Journal of Medicine 377 (19), 1824-1835, 201721792017
2-) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ...The lancet oncology 14 (3), 249-256, 20137512013
3-) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studySJ O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ...Annals of Oncology 21 (8), 1712-1717, 20106222010
4-) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findingsF Belli, A Testori, L Rivoltini, M Maio, G Andreola, MR Sertoli, G Gallino, ...Journal of Clinical Oncology 20 (20), 4169-4180, 20025442002
5-) Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled …PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ...The Lancet Oncology 21 (11), 1465-1477, 20205112020